A groundbreaking antibody treatment for Alzheimer’s disease developed by an Israeli scientist is currently headed toward a Phase I clinical trial. If successful, the treatment could become a game-changer for the disorder, modifying its course and preventing its progression.

The therapy, developed by ImmunoBrain Checkpoint (IBC), a biopharmaceutical company focused on immunotherapies for neurodegenerative diseases like Alzheimer’s, is based on over 20 years of research from a team at Weizmann Institute of Science headed by Professor Michal Schwartz of the Department of Neurobiology.